Terremoto Biosciences Granted FDA Fast Track Designation for TER-2013, an AKT1-Selective Small Molecule Inhibitor for Breast Cancer

Terremoto Biosciences announced that it received Fast Track Designation granted for TER-2013 in HR+/HER2- breast cancer with AKT/PI3K/PTEN-alterations following endocrine therapy and CDK4/6 inhibitor therapy The post Terremoto Biosciences Granted FDA Fast Track Designation for TER-2013, an AKT1-Selective Small Molecule Inhibitor for Breast Cancer first appeared on Terremoto .